Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Aquaporin-2 (AQP2) is a major target molecule of antidiuretic hormone (ADH). It regulates the water permeability of collecting ducts and plays an important role in urine concentration. Similar to other aquaporins, the three-dimensional structure of AQP2 is an "hourglass model" that exists as a tetramer in the cell membrane. Each monomer consists of one peptide chain, its N-terminus and the C-terminus are located on the cytoplasmic side of the cell membrane. The peptide chain consists of six long alpha helices on both sides of the membrane and 5 rings are connected (A-E loop). A monomer is a separate functional unit with a channel tube in the center. AQP2 is mainly composed of loop C and loop D to form a water molecule channel tube.
AQP2 is mainly expressed in the main cells of the renal collecting duct and is also expressed in the inner ear, male and female reproductive systems. AQP2 is distributed in the apical plasma membrane and vesicles near the apical plasma membrane in the main cells of the renal collecting duct. In recent years, AQP2 expression has also been found in renal cysts and polycystic kidney epithelial cells.
AQP2 Function
The most important function of AQP2 is to mediate transmembrane transport of water. AQP2 plays an important role in urine concentration and regulating the water balance of the human kidney. When the plasma osmotic pressure is increased, the neurohypophyseal releases ADH into the blood circulation, and binds to the V2 receptor (mainly distributed on the basal side of the main cell of the collecting duct), causing the AQP2-containing vesicles under the plasma membrane of the main cell to move toward the apical plasma membrane. Finally, the expression of apical plasma membrane AQP2 is increased and the ability of urine concentration is enhanced. In addition, there are a large number of V2 receptors and AQP2 expression in the inner ear cochlea and AQP2 plays an important role in regulating the inner lymphatic balance of the inner ear. Zhang et al. found AQP2 expression in female endometrium and vaginal mucosa epithelium, and AQP2 was associated with endometrial damage in the process of controlled ovarian stimulation during embryo transfer.
AQP2 Regulation Mechanism
The expression of AQP2 and "shuttle" are mainly regulated by ADH. ADH is secreted by the pituitary gland. The regulation of AQP2 by ADH mainly through two mechanisms: 1. short-term regulation: regulation of the distribution of AQP2 in the main cells of the collecting duct but the total amount of AQP2 in the cells is unchanged. Then the vesicles containing AQP2 are moved to the apical plasma membrane of the main cell, increasing the water permeability of the apical plasma membrane. 2. Long-term regulation: regulation of the total amount of AQP2 in the main cells of the collecting duct, increasing the transcription and translation level of AQP2.
Short-term adjustment
ADH binds to the V2 receptor and activates the adenylate cyclase (AC) near the cytoplasmic side of the cell membrane, hydrolyzing and cyclizing ATP to form a second messenger cAMP, thereby activating the cAMP/PKA signaling pathway. Then the AQP2-containing vesicles are moved to the apical plasma membrane. In addition, other protein kinases may also be involved, such as Akt, Sgk, myosin light chain kinase, CaM-dependent protein kinase, protein kinase C and the like. ADH regulates AQP2 with AQP2 phosphorylation. It has been found that four serines (Ser256, Ser261, Ser264, Ser269) on the AQP2 protein can be regulated by phosphorylation. PKA increased phosphorylation at Ser256, Ser264, and Ser269, and decreased phosphorylation at Ser261. Tamma et al. found that the phosphorylation of Ser256 increased the vesicles containing AQP2 to the apical plasma membrane. The phosphorylation of Ser261 could inhibit this process. The phosphorylation of Ser264 and Ser269 remains to be further studied. Sjöhamn et al. found that other protein kinases such as c-Jun amino terminal kinase, p38, cd1, cd5 reduced phosphorylation of Ser261. In addition, Sasaki et al. found that ADH bind to the V2 receptor and activated the G protein Gq, moving the AQP2-containing vesicles to the apical plasma membrane through the IP3-Ca2+ signaling pathway.
Figure 1. Identification of a PKA-independent pathway controlling AQP2 trafficking. Schematic model. ER, endoplasmic reticulum. (Tamma, et al. 2014).
Long-term adjustment
The newly produced AQP2 protein is transported from the endoplasmic reticulum to the membrane under the guidance of a signal peptide. It was previously thought that AQP2 was directly transported to the apical plasma membrane of the collecting duct, but Naofumi et al. observed the vesicles in the collecting duct cells by confocal microscopy at 4 °C. It was found that part of AQP2 moved to the basal side of the cell and then moved to the apical plasma membrane. The transport mechanism from the basal side to the apical plasma membrane is independent of Rab11.
ADH is not the only factor regulating AQP2 expression. Al et al. have found that Nitrogen monoxide (NO) can promote renal water reabsorption to increase the distribution ratio of AQP2 in the apical plasma membrane and vesicles of collecting duct cells. Ortiz et al. found that the decrease in the activity of Nitric oxide Synthase (NOS) caused a decrease in AQP2 expression in the apical plasma membrane of collecting duct cells. Studies have found that excessive urinary calcium concentration reduces the expression of AQP2 on the plasma membrane at the apical end of the collecting duct, which decreases the function of urine concentration.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.